switching from tirzepatide to semaglutide dosage Guide In 2026 How to Switch from Tirzepatide

Retrospective cohort studies show that these agents do not increase the risk of IBD flares or gastrointestinal-specific adverse events compared to the general population (9396)

10.1074/jbc.M610447200 J

Researchers study this formulation to analyze receptor-specific signaling mechanisms and coordinated endocrine responses

This studys results are from the After an average follow-up of about 3.5 years, scientists discovered that adverse kidney-related events such as a significant decline in kidney function, death from kidney causes, or onset of persistent macroalbuminuria were experienced by 22% fewer participants in the group receiving semaglutide injections compared to the placebo group